Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(158 produtos)
- Bcr-Abl(113 produtos)
- EGFR(598 produtos)
- FAK(72 produtos)
- FLT(90 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(182 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(90 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(53 produtos)
- VDA(2 produtos)
- VEGFR(250 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2040 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Izalontamab
CAS:Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers.Pureza:95%+ - 95.3% (SDS-PAGE); 99.2% (SEC-HPLC)Cor e Forma:LiquidPonezumab
CAS:Ponezumab (PF-04360365), a humanized IgG2 antibody, lowers Aβ in the CNS & boosts mice memory. Used in Alzheimer's research.Cor e Forma:LiquidAnbenitamab
CAS:Anbenitamab (KN-026) is a bispecific HER2 antibody for metastatic breast cancer research, blocking HER2 pathways and mediating ADCC.Cor e Forma:LiquidEGFR T790M/L858R-IN-8
CAS:EGFRT790M/L858R-IN-8 (compound 9) is a potent inhibitor of EGFR, specifically targeting the EGFRT790M/L858R mutations with an IC50 of 56.8 μM. This compound does not show significant antiproliferative effects on cancer cell lines A549, A431, and NHI-H1975.Fórmula:C16H11BrN2O3Cor e Forma:SolidPeso molecular:359.17Tarcocimab
CAS:Tarcocimab (OG1953) is a humanized IgG1 monoclonal antibody targeting VEGFA, researched for RVO and wet AMD.Cor e Forma:LiquidFutuximab
CAS:Futuximab is a chimeric monoclonal antibody targeting EGFR, commonly used in combination with zatuximab to form Sym004.Pureza:95% - 97.5% (SDS-PAGE); 96.3% (SEC-HPLC)Cor e Forma:LiquidFaricimab
CAS:Faricimab,Bispecific antibody targeting Ang-2/VEGF-A. Prevents retinal I/R injury. Improves vision in w-AMD, DME, RVO.Pureza:>95% (SDS-PAGE); >95% (SEC-HPLC) - >95% (SDS-PAGE); >95% (SEC-HPLC)Cor e Forma:LiquidIbrutinib-d5
CAS:Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.Fórmula:C25H24N6O2Pureza:98%Cor e Forma:SolidPeso molecular:445.53Dasatinib-d8
CAS:Dasatinib D8 is deuterium-labeled dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.Fórmula:C22H26ClN7O2SPureza:98%Cor e Forma:SolidPeso molecular:496.06Apatinib-d8
CAS:Apatinib-d8 is a deuterated compound of Apatinib. Apatinib has a CAS number of 811803-05-1. Apatinib is an orally bioavailable and specific VEGFR2 inhibitor (IC50: 1 nM). In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.Fórmula:C24H15D8N5OPeso molecular:405.52MAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFórmula:C20H11Cl2N3OPureza:98%Cor e Forma:SolidPeso molecular:380.23ZM323881 hydrochloride
CAS:ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.Fórmula:C22H19ClFN3O2Pureza:99.43%Cor e Forma:SolidPeso molecular:411.86EGFR-IN-109
CAS:EGFR-IN-109 (compound 4), an EGFR inhibitor, displays IC 50 values of 25.8 nM for EGFR WT and 182.3 nM for EGFR T790M. This compound halts the growth of cancer cells at the G2/M phase and triggers both early and late apoptosis. It is applicable in cancer research [1].Fórmula:C12H16N4OSCor e Forma:SolidPeso molecular:264.35Icotinib
CAS:Icotinib (Conmana) is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.Fórmula:C22H21N3O4Pureza:99.76% - 99.94%Cor e Forma:SolidPeso molecular:391.42Dovitinib Dilactic Acid
CAS:Dovitinib dilactic acid: multitarget RTK inhibitor for FLT3/c-Kit (IC50=1-2 nM), FGFR1/3, VEGFR1-4 (IC50=8-13 nM), less effective on InsR, EGFR. Phase 4.Fórmula:C21H21FN6O·2C3H6O3Pureza:98%Cor e Forma:SolidPeso molecular:572.59GZD856 formic
CAS:GZD856 formic inhibits PDGFRα/β (IC50: 68.6, 136.6 nM) & Bcr-Abl (IC50: 19.9, 15.4 nM), with antitumor properties.Fórmula:C30H29F3N6O3Cor e Forma:SolidPeso molecular:578.58HVH-2930
CAS:HVH-2930 is an inhibitor of Heat Shock Protein 90 (HSP90). It suppresses the cell viability of BT474 (Trastuzumab sensitive) and JIMT-1 (Trastuzumab resistant) by downregulating HSP90 client proteins such as HER2, p-HER2, AKT, p-AKT, cyclin D1, and survivin, with IC50 values of 6.86 μM and 4.42 μM, respectively. Additionally, HVH-2930 demonstrates antitumor efficacy in a mouse model and exhibits favorable pharmacokinetic properties in vivo.Fórmula:C29H36N4O3Cor e Forma:SolidPeso molecular:488.62ALK5-IN-79
CAS:ALK5-IN-79 (compound 57), an ALK inhibitor, exhibits anticancer activity by inhibiting the TGF-β1/SMAD signaling pathway. It effectively reduces the production of extracellular matrix (ECM) and collagen deposition. Moreover, ALK5-IN-79 demonstrates satisfactory pharmacokinetic (PK) properties and favorable in vivo tolerance.Fórmula:C23H27N7OCor e Forma:SolidPeso molecular:417.51(3S,4S)-Tofacitinib
CAS:(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37Erlotinib mesylate
CAS:<p>Erlotinib: reversible inhibitor binding to ATP site of epidermal growth factor receptor.</p>Fórmula:C23H27N3O7SPureza:98%Cor e Forma:SolidPeso molecular:489.54
